September 2011 in “Urology” Urinary PSA could be an early marker for enlarged prostate.
1 citations
,
June 2025 in “Scientific Reports” Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.